Loading…
Shanghai clinical-stage biotech developing small-molecule drugs for cancer and inflammatory diseases, largely pre-revenue.
Shanghai clinical-stage biotech developing small-molecule drugs for cancer and inflammatory diseases, largely pre-revenue.
In one line: A small, China-based clinical biotech.
Moat: none (IP / patents). Pipeline value depends on trial results and patents, not yet a commercial franchise.
Headquarters: Shanghai, China · Employees: 182
Size InventisBio (688382.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.19B, the 1979th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥13.68 on 6 Nov 2026.
Performance Over six months the shares fell 41.3%, against -8.1% for the median peer and -16.4% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue fell 60.6% over the last twelve months (peer median +11.3%); the operating margin is -562.8% (peer median 10.6%).
Valuation It trades at 94.5× enterprise value to sales against a peer median of 3.8× (2nd most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is -61%, so the hurdle is +71 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥71.1M | CN¥37.3M | CN¥169M | CN¥186M | CN¥0 |
| Revenue growth | — | -78% | -9% | — | — |
| Gross profit | CN¥66.2M | CN¥16.1M | CN¥145M | CN¥163M | -CN¥19.9M |
| EBITDA | n/a | -CN¥335M | -CN¥261M | -CN¥305M | -CN¥500M |
| Net income | -CN¥379M | -CN¥317M | -CN¥240M | -CN¥284M | -CN¥483M |
| Free cash flow | CN¥371M | -CN¥146M | -CN¥228M | -CN¥307M | -CN¥485M |
| Capital expenditure | CN¥7.50M | CN¥6.92M | CN¥7.56M | CN¥6.29M | CN¥7.69M |
| Total debt | CN¥17.5M | CN¥22.1M | CN¥23.9M | CN¥11.6M | CN¥27.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| InventisBio 688382.SS | $1.19B | -41% | -61% | -563% | 94.5× | 10.4% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $49.7B | -6% | +6% | 27% | 8.8× | 14.9% |
| BeOne Medicines 688235.SS | $45.8B | +19% | +28% | 15% | 6.8× | 23.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688382.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -21.1% | -1.1% | 3rd lowest of 21 |
| 6-month return | -41.3% | -8.1% | 3rd lowest of 21 |
| Distance from 52-week high | -60.5% | -31.2% | 2nd lowest of 21 |
| Revenue growth (TTM) | -60.6% | +11.3% | lowest of 19 |
| Operating margin | -562.8% | 10.6% | lowest of 20 |
| EV / Sales | 94.5× | 3.8× | 2nd most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 10.4% | 3.3% | 3rd most demanding of 12 |
| Growth delivered (Del g) | -60.6% | +11.3% | lowest of 12 |
| Hurdle (Req g minus delivered) | +71.1 pp | -5.5 pp | most demanding of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| InventisBio 688382.SS | China | $1.19B | -41% | -61% | -563% | 94.5× | 10.4% | -60.6% |
| Jiuzhitang 000989.SZ | China | $1.19B | -13% | +46% | 19% | 2.6× | -3.7% | -9.0% |
| GC Biopharma 006280.KS | South Korea | $1.18B | +2% | -3% | 4% | 0.8× | 8.3% | +5.8% |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.18B | -4% | -9% | 11% | 2.5× | 5.8% | +11.3% |
| Vetoquinol VETO.PA | France | $1.17B | +22% | -1% | 15% | 1.6× | -3.0% | +4.2% |
| Cosmo CMHC.SW | Switzerland | $1.17B | -25% | -45% | -13% | 8.3× | n/a | n/a |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1.17B | +28% | +24% | 6% | 6.3× | 16.2% | +19.4% |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.21B | -8% | -2% | 15% | 4.5× | 4.5% | -1.2% |
| North China Pharmaceutical 600812.SS | China | $1.17B | -8% | -21% | 5% | 2.5× | 1.4% | -4.2% |
| Amphastar Pharmaceuticals AMPH | United States | $1.21B | +50% | +1% | 16% | 2.2× | 3.3% | +15.5% |
| Everest Medicines 1952.HK | Hong Kong | $1.22B | -20% | +193% | -5% | 3.5× | n/a | n/a |
| Omeros OMER | United States | $1.22B | +14% | n/a | -190% | 36.2× | n/a | n/a |
| Seaport Therapeutics SPTX | United States | $1.15B | +34% | n/a | n/a | n/a | n/a | n/a |
| MedinCell MEDCL.PA | France | $1.15B | -1% | -23% | -131% | 51.0× | n/a | n/a |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.13B | -34% | +32% | 14% | 22.0× | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.13B | -18% | +9% | 28% | 4.6× | 1.5% | +18.7% |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.13B | -18% | +17% | 20% | 2.5× | 1.1% | +22.8% |
| MannKind MNKD | United States | $1.25B | +11% | +30% | 3% | 4.0× | n/a | n/a |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.26B | -57% | +81% | -305% | 111.4× | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.27B | -29% | +14% | 11% | 3.0× | 11.7% | +18.1% |
| ST Pharm 237690.KS | South Korea | $1.12B | -52% | +26% | 18% | 3.8× | n/a | n/a |